Physician profile
Ginger Mcdaniel
NPI 1477889590
$26,774.50
in general payments reported to CMS, 2019-2025
27 companies · $9,423 in 2025
The $9,423 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,257 · 2022: $1,045 · 2023: $6,027 · 2024: $8,022 · 2025: $9,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,450 · Travel and Lodging: $801 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,022.50 |
| Food and Beverage | $6,450.01 |
| Travel and Lodging | $800.83 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,765.81 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $5,526.45 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,507.61 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,089.00 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $849.93 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $738.32 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $343.84 | 2021-2025 | Vemlidy, Livdelzi |
| Ardelyx, INC. | $285.25 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $244.99 | 2023-2025 | |
| Madrigal Pharmaceuticals | $223.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $162.56 | 2024 | Stelara |
| Celgene Corporation | $157.69 | 2022-2024 | Zeposia |
| Evoke Pharma, INC. | $153.79 | 2023-2025 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $120.74 | 2022-2024 | Dupixent |
| Celltrion USA INC. | $108.37 | 2025 | Vegzelma |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $104.29 | 2023-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $84.50 | 2022-2023 | Sutab, Suflave |
| Lilly USA, LLC | $74.97 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $39.39 | 2021 | |
| Ironwood Pharmaceuticals, INC | $36.60 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $32.19 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $31.82 | 2024-2025 | Vowst |
| Intra-Sana Laboratories | $23.09 | 2022 | |
| Merck Sharp & Dohme LLC | $20.94 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.74 | 2023 | |
| Ferring Pharmaceuticals INC. | $14.81 | 2024 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.